Cantor Fitzgerald set a $18.00 price objective on Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) in a research note released on Saturday. The firm currently has a buy rating on the biotechnology company’s stock.
AUPH has been the topic of several other research reports. BidaskClub lowered Aurinia Pharmaceuticals from a hold rating to a sell rating in a report on Wednesday. HC Wainwright reiterated a buy rating and issued a $12.00 target price on shares of Aurinia Pharmaceuticals in a research note on Wednesday, May 2nd. Finally, Zacks Investment Research upgraded Aurinia Pharmaceuticals from a hold rating to a buy rating and set a $6.75 target price on the stock in a research note on Monday, July 16th. One research analyst has rated the stock with a sell rating, two have given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of Buy and a consensus price target of $11.14.
Aurinia Pharmaceuticals traded down $0.08, hitting $5.37, during midday trading on Friday, Marketbeat.com reports. The company’s stock had a trading volume of 379,689 shares, compared to its average volume of 396,422. Aurinia Pharmaceuticals has a 12 month low of $4.41 and a 12 month high of $7.60. The company has a market capitalization of $460.40 million, a price-to-earnings ratio of -5.84 and a beta of 2.18.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Stifel Financial Corp lifted its holdings in shares of Aurinia Pharmaceuticals by 98.4% during the first quarter. Stifel Financial Corp now owns 21,718 shares of the biotechnology company’s stock worth $113,000 after purchasing an additional 10,772 shares during the period. DRW Securities LLC acquired a new stake in shares of Aurinia Pharmaceuticals in the first quarter worth approximately $162,000. Stanley Laman Group Ltd. acquired a new stake in shares of Aurinia Pharmaceuticals in the second quarter worth approximately $276,000. Creative Planning boosted its stake in shares of Aurinia Pharmaceuticals by 8.2% in the second quarter. Creative Planning now owns 171,200 shares of the biotechnology company’s stock worth $964,000 after acquiring an additional 13,000 shares during the last quarter. Finally, Ironwood Investment Management LLC boosted its stake in shares of Aurinia Pharmaceuticals by 18.0% in the second quarter. Ironwood Investment Management LLC now owns 218,568 shares of the biotechnology company’s stock worth $1,231,000 after acquiring an additional 33,279 shares during the last quarter. 25.73% of the stock is owned by institutional investors and hedge funds.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.
Further Reading: Penny Stocks
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.